Details of the Drug Combination

General Information of Drug Combination (ID: DC78K1O)

Drug Combination Name
Rifabutin Vonoprazan
Indication
Disease Entry Status REF
Helicobacter Pylori Infection Phase 4 [1]
Component Drugs Rifabutin   DM1YBHK Vonoprazan   DMO6315
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Rifabutin
Disease Entry ICD 11 Status REF
Mycobacterium infection 1B10-1B21 Approved [2]
Tuberculosis 1B10-1B14 Approved [2]
Rifabutin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA-directed RNA polymerase (RNAP) TTHKJLN NOUNIPROTAC Modulator [5]
------------------------------------------------------------------------------------
Rifabutin Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [6]
------------------------------------------------------------------------------------
Indication(s) of Vonoprazan
Disease Entry ICD 11 Status REF
Helicobacter infection DA42-DA63 Approved [3]
Gastroesophageal reflux disease DA22.Z Phase 3 [4]
Vonoprazan Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Gastric H(+)/K(+) ATPase (Proton pump) TTLOKXP ATP4A_HUMAN; ATP4B_HUMAN Modulator [3]
------------------------------------------------------------------------------------
Vonoprazan Interacts with 5 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [7]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [7]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Metabolism [7]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [7]
Sulfotransferase 2A1 (SULT2A1) DE0P6LK ST2A1_HUMAN Metabolism [7]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT05874544) Rescue Therapy for Helicobacter Pylori Infection
2 Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2008
4 ClinicalTrials.gov (NCT02388724) Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Patients With Erosive Esophagitis. U.S. National Institutes of Health.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther. 1998 Apr;63(4):414-21.
7 In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2017 Dec;47(12):1027-1034.